Genentech is currently experiencing a supply shortage for Nutropin AQ® NuSpin in the United States. See the latest update on Nutropin (somatropin) supply here.
The FDA approved Genentech's first growth hormone product in 1985.
Genentech is dedicated to biologic science and committed to patients.
Nutropin AQ® NuSpin® is designed to be simple.
Supporting you throughout treatment
Sebastian, a Nutropin patient, and his mom, Andrea, walk through the steps associated with using the NuSpin device for Nutropin therapy.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.